Geron Corporation
Geron Corporation develops therapeutics for myeloid hematologic malignancies. Imetelstat, a telomerase inhibitor, is in Phase 3 clinical trials to treat low/intermediate-1 risk MDS and intermediate-2/high-risk myelofibrosis. It inhibits the uncontrolled proliferation of malignant stem/progenitor cells. The company was incorporated in 1990 and is headquartered in California.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 10.3% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 17.9% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data